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Summary
Patients with diabetes are at risk of early renal function de-
cline. Therefore, kidney function needs monitoring at least
once per year. Once the glomerular filtration rate (GFR) is
less than 60 ml/min, the pharmacokinetics of antidiabetic
drugs may be altered. Sulfonylurea and glinide therapies
are associated with a risk of hypoglycaemia which is in-
creased in the presence of renal impairment. Most sulf-
onylureas must be discontinued once GFR is <60 ml/min.
Some glinides may be continued beyond this threshold, in
particular repaglinide, which may be used in dialysis pa-
tients. In the absence of comorbidities, metformin can be
continued at lower doses until a GFR of 45 ml/min, but
must be withdrawn in case of dehydration or during the ad-
ministration of a nephrotoxic drug including dye for radi-
ological investigations. Glitazones may worsen water and
sodium retention in patients with renal impairment. The
pharmacokinetics of all DPP-IV inhibitors except linaglipt-
in are altered with impaired renal function. Only sitagliptin,
saxagliptin and linagliptin may be used in advanced kidney
disease, but experience is as yet very limited. GLP-1 ag-
onists are contraindicated in moderate to advanced kidney
disease.
Key words: hypoglycaemic drugs; renal failure; diabetic
nephropathy
Introduction
Diabetes increases the risk of chronic kidney disease by
2.6-fold [1] and the risk of renal death by 3-fold [2]. A
large number of patients with diabetes mellitus will at some
point have an altered renal function. Once the estimated
glomerular filtration rate (eGFR) falls below 60 ml/min,
a subject’s antidiabetic therapy needs to be re-evaluated.
Some oral antidiabetic drugs are formally contraindicated,
and others require dose reduction. In spite of these recom-
mendations, the dose adjustment is seldom performed [3].
The risk of hypoglycaemia increases with increasing ren-
al impairment, and hypoglycemia from antidiabetic drug
therapy is among the four leading causes of hospitalisation
for adverse drug reactions in the elderly [4]. This paper
reviews the use of oral antidiabetic drugs in patients with
chronic kidney disease (CKD) and discusses the available
treatment options, including recent data on incretins.
Diabetic kidney disease is on the rise in many industrialised
nations, and is the leading cause of end-stage renal disease.
Overall, the rising incidence of type 2 diabetes, the longer
survival of diabetic subjects, the aging population, and
demographic expansion explain the significant increase in
the number of diabetic subjects who live to reach end-stage
renal disease. Recent data from the Swiss Canton of Vaud
confirm a substantial increase in the number of diabetic
dialysis subjects over an 8-year period [5].
In the Colaus study, a cohort study involving over 6000
subjects between the ages of 35 and 75 living in Lausanne,
Switzerland [6], kidney disease, defined by the presence of
≥ stage 3 CKD (estimated MDRD GFR <60 ml/min) and/
or the presence of microalbuminuria or proteinuria, was
present in approximately 30% of diabetic subjects (person-
al communication, M. Bochud). In this population study,
around 10% of adult diabetic subjects had an eGFR
<60 ml/min. The use of oral antidiabetic drugs should be
reviewed in all of these subjects.
Renal characterisation of patients
with diabetes
At least annual monitoring of renal function is recommen-
ded for all adult diabetic subjects with the determination
of creatinine levels, calculation of the eGFR using any
of the available formulas (MDRD, CKD-EPI, Cockroft-
Gault), and determination of the urinary albumin/creatinine
ratio [7]. The MDRD Study equation, which requires only
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the serum creatinine concentration and the patient’s age, is
the most commonly used GFR formula and can be auto-
matically calculated by the laboratories. It has been evalu-
ated in patients with a GFR <60 ml/min, and thus should
be used for this group. The best formula for higher GFRs
is the CKD-Epi formula or for all levels of GFR with a
small variation is the Cystatin-C based GFR formula (GFR
= (86.7/Cystatin-C)-4.2), if thyroid function is normal.
Since the 1990’s, more intensive hypoglycaemic and an-
tihypertensive treatment has been validated as nephropro-
tective based on its ability to normalise or slow the pro-
gression of proteinuria. Over time, more stringent blood
glucose and blood pressure goals have indeed lowered the
incidence of proteinuria in the diabetic population [8].
However, US epidemiological data from NHANES show
that the incidence of renal impairment, as defined by an
eGFR <60 ml/min, has not decreased. In light of these sur-
prising results, world experts are calling for improved ren-
al characterisation of diabetic patients and for the develop-
ment of new drugs targeting other pathways implicated in
the pathogenesis of diabetic kidney disease.
Hypoglycemic treatments and the
kidney
Glycaemic control is the only effective therapeutic inter-
vention for the primary prevention of diabetic kidney dis-
ease in normoalbuminuric and normotensive subjects. In
type 2 diabetic subjects, the UKPDS study has demon-
strated that intensive hypoglycaemic treatment decreases
the incidence and progression of microalbuminuria and
is independent of the type of antidiabetic treatment used
(metformin, sulfonylurea, or insulin). To date, it has not
been possible to demonstrate that any particular antidiabet-
ic drug is more effective than any other in terms of neph-
roprotection. The main objective is to achieve an HbA1C of
<7% while ensuring that the conditions of antidiabetic drug
use are compatible with renal function [9, 10].
Oral antidiabetic drugs in chronic
kidney disease
The ideal antidiabetic drug lowers blood glucose without
increasing the risk of hypoglycaemia or weight gain.
Among the available oral antidiabetic drugs, sulfonylureas
and glinides are associated with a risk of hypoglycaemia.
These drugs stimulate the release of insulin from pancreatic
β-cells following the interaction with ATP-dependent po-
tassium channels, independently from glucose levels.
When sulfonylureas are combined with insulin, the risk of
hypoglycaemia may increase more than 14-fold [11]. Ren-
al impairment is a major risk factor for hypoglycaemia. Pa-
tients taking drugs associated with a risk of hypoglycaemia
(sulfonylureas, glinides, insulin) need to undergo system-
atic blood glucose monitoring when driving to make sure
that blood glucose is >5 mmol/l [12]. Legal issues regard-
ing these recommendations are currently being revised in
Switzerland.
Sulfonylureas
Sulfonylureas have been used for the management of
type 2 diabetes for over 50 years. First-generation sulf-
onylureas (chlorpropamide, tolbutamide) have been aban-
doned because of the risk of prolonged hypoglycaemia.
Second-generation sulfonylureas (glibenclamide = glybur-
ide, glimepiride, gliclazide) have shorter half-lives
(5–15 hours), but their duration of action may be as long
as 24 hours. The hypoglycaemic effect of sulfonylureas is
faster and more potent compared to metformin or rosigl-
itazone, but may diminish over time [13]. The risk of hy-
poglycaemia induced by sulfonylureas in CKD is due to the
accumulation of active metabolites. Other factors may con-
tribute to the risk of hypoglycaemia, such as dose, omission
of carbohydrates during meals, malnutrition, excessive al-
cohol intake, hepatic dysfunction, heart failure, advanced
age, and interactions with some drugs (aspirin, sulfonam-
ides, gemfibrozil, warfarin, etc.) which may shift sulf-
onylureas from their plasma protein binding sites.
Glibenclamide (= glyburide) (Daonil®; 2.5–10 mg/day) is
metabolised by the liver, and is eliminated equally in bile
and urine. Some of its metabolites are active and may ac-
cumulate in CKD although hepatobiliary elimination may
partially compensate for the decrease in renal elimination.
Hypoglycaemic episodes may be severe and last longer
than 24 hours in the presence of renal impairment. Gliben-
clamide should be used with caution in patients with mild
CKD (eGFR 60–90 ml/min) and is contraindicated in ≥3
CKD stages (eGFR <60 ml/min).
Glimepiride (Amaryl®, 1–8 mg/day) is metabolised by the
liver to two main metabolites, one of which has hy-
poglycaemic activity. In patients with renal impairment,
these metabolites can accumulate. Although its half-life is
5–7 hours, the drug may produce hypoglycaemic episodes
that are severe and may persist for more than 24 hours
Figure 1
Antidiabetic treatment in chronic renal failure according to the
KDIGO staging of CKD. Adapted from: Schernthaner G, Ritz E,
Schernthaner GH. Strict glycaemic control in diabetic patients with
CKD or ESRD: beneficial or deadly? Nephrol Dial Transplant.
2010;25:2044–7 [25] (© 2010, Oxford University Press. Reprinted
with permission).
Recommendations adapted to stages of CKD based on a
consensus from pharmacological data, Swiss and international
recommendations.
1 Limited experience (dotted line); 2 monitor for fluid retention;
3 avoid introducing as new therapy or if conditions increasing lactic
acidosis risk.
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in patients with CKD. As with glibenclamide, the use of
glimepiride is contraindicated in patients with a GFR of
<60 ml/min. Dosage adjustment is required in mild CKD.
Gliclazide (Diamicron® 80–320 mg/day; DiamicronMR®
30–120 mg/day) is metabolised by the liver to inactive
metabolites, which are eliminated mainly in the urine
(80%). Various studies have shown that among the sulf-
onylureas available in Switzerland, gliclazide poses a lower
risk for severe hypoglycaemia than glibenclamide and
glimepiride. Although no data are available in patients with
severe renal impairment, studies have shown neither phar-
macokinetic modifications of the drug nor a risk of hy-
poglycaemia in patients with a GFR >40 ml/min. In
Switzerland, gliclazide is the only sulfonylurea that can be
used in subjects with a GFR of 40–60 ml/min. However, it
must be stopped once GFR falls below 40 ml/min.
Glinides
Two glinides are available: repaglinide and nateglinide.
These drugs are characterised by a rapid onset and a short
duration of action. They are however less potent than sulf-
onylureas. They are only taken prior to meals that contain
carbohydrates, and efficiently reduce postprandial blood
glucose levels. The risk of hypoglycaemia is lower than
with sulfonylureas.
Repaglinide (Novonorm®, 0.5–12 mg/day) is mainly
metabolised by the liver, and less than 10% is recovered
in urine. Although renal impairment may slightly prolong
its half-life, the use of repaglinide is not contraindicated in
patients with renal impairment or dialysis patients. A pre-
prandial dose of 0.5–4 mg should be titrated according to
the postprandial blood glucose response.
Nateglinide (Starlix®, 60–360 mg/day) is metabolised by
the liver with a half-life of 1.2–1.8 hours. Parent drug and
certain active metabolites may accumulate in case of renal
impairment. Therefore, the drug should be used with cau-
tion in patients with kidney disease.
Metformin (Glucophage®, 500-2,550 mg/day)
International recommendations consider metformin as the
first choice for the treatment of type 2 diabetes. Metformin
has been available for over 50 years and has the advantage
of effectively lowering blood glucose levels and favours
weight loss, without increasing the risk of hypoglycaemia.
The principal action of metformin is the inhibition of hep-
atic glucose production. It also facilitates the insulin-me-
diated peripheral glucose uptake. Unchanged drug is elim-
inated via the kidneys by glomerular filtration and tubular
secretion. Therefore, there is a risk of accumulation of the
drug in case of renal impairment. This situation has been
linked with a risk of lactic acidosis (estimated at 5/100000
patient-years) which may carry a mortality of up to 40%.
However, it should be emphasised that this risk is lower
than the mortality/morbidity risk associated with severe hy-
poglycaemia during sulfonylurea or insulin treatment in pa-
tients with CKD. Lactic acidosis is often accompanied by
other predisposing conditions such as heart failure, hep-
atic dysfunction, advanced age, excessive alcohol intake,
administration of iodinated contrast dye, hypoxaemia, and
shock. A causal relationship between lactic acidosis and
the accumulation of metformin has never been clearly
demonstrated [14, 15]. In fact, the major cause of severe
lactic acidosis appears to be rather linked to the risk of hyp-
oxia. However, many of us have shared the clinical exper-
ience of an elderly patient taking metformin and suffering
from dehydration, acute renal failure and severe acidosis.
Furthermore, extreme overdose of metformin (e.g., in the
case of suicidal attempt) has been associated with severe,
lethal lactic acidosis, even in otherwise healthy individuals
[16]. Therefore, it is important to re-emphasise the need to
discontinue metformin in case of vomiting, diarrhea, oth-
er causes of dehydration as well as investigation with iod-
inated dye. We suggest exercising great caution and dose
adjustment with the evaluation of renal function more than
once per year in patients already on metformin, whose
GFR is 45–60 ml/min and stopping treatment once GFR is
<45 ml/min. This is more strict than the limit of 30 ml/min
as proposed by Lipska, but also safer [15]. Gastric bypass
increases the bioavailability of metformin by 50% [17] and
the dose should be therefore reduced with milder degrees
of CKD.
Glitazones
Glitazones are potent insulin sensitisers which have been
available for the management of type 2 diabetes for over
a decade. The metabolic effects result from the improve-
ment in insulin sensitivity in the liver, adipose tissue, and
muscle, leading to durable glycaemic control. Their arrival
on the U.S. market was received with enthusiasm, leading
to the widespread prescription although evidence of long-
term safety was still lacking. The risk of water and sodium
retention, increased by renal impairment and insulin ther-
apy, was identified soon after their market entry. This risk,
an issue with rosiglitazone (Avandia®) and pioglitazone
(Actos®, 15–45 mg/day), affects 5–15% of patients treated.
Seven years after its market entry, concerns were raised
about the cardiovascular safety of rosiglitazone, eventually
leading to its removal in 2010. The cardiovascular safety
studies of pioglitazone are reassuring for the time being.
Glitazones are also associated with a risk of osteoporosis,
especially in postmenopausal women. The recent identific-
ation of a possible risk of bladder cancer with pioglitazone
has resulted in the recommendation to avoid its use in pa-
tients with a history of bladder cancer and to evaluate the
risk factors of bladder cancer (age, tobacco use, exposure
to certain chemotherapy agents). Neither the European nor
the U.S. regulatory authorities have suggested or reques-
ted that pioglitazone be removed from the market. Pioglit-
azone continues to be approved for the treatment of type 2
diabetes in patients who do not tolerate or are inadequately
controlled by metformin. However, both France and Ger-
many have removed pioglitazone from the market and re-
cently Swissmedic limits the use of pioglitazone to two
years and recommends continuing therapy only if the be-
nefits of pioglitazone overcome the risk of bladder can-
cer. The pharmacokinetics of pioglitazone are not altered
by renal impairment, and there is no need for dose adjust-
ment in this setting. Despite this advantage and the fact
that pioglitazone does not induce hypoglycaemia, the drug
should be used with caution in CKD because of the risk of
water and sodium retention and heart failure. Data regard-
ing its safety in dialysis patients are as yet very limited. We
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recommend great caution when using pioglitazone in pa-
tients whose eGFR is <60 ml/min.
Alpha-glucosidase inhibitors (Glucobay®, 50–300 mg/
day)
These drugs slow the intestinal carbohydrate absorption
through the inhibition of the intestinal alpha-glucosidase
enzyme. Their hypoglycaemic efficacy is low, and side ef-
fects of flatulence and diarrhea limit their use. These med-
ications are occasionally prescribed for reactive hy-
poglycaemia in patients who have undergone gastric by-
pass surgery. The use of acarbose is not recommended in
patients with renal impairment because of the risk of accu-
mulation and lack of experience.
GLP-1 receptor agonists and DPP4 Inhibitors
The mechanism of action of GLP-1 receptor agonists and
DPP4 enzyme inhibitors is based on the physiology of in-
cretin hormones. They may occasionally be considered for
use in patients with renal impairment.
The GLP-1 hormone plays a central role in glucose homeo-
stasis. It is secreted by intestinal mucosal L-cells in re-
sponse to food intake. GLP-1 reduces postprandial blood
glucose levels by stimulating insulin production and secre-
tion in a glucose-dependent manner. This stimulation oc-
curs only in the presence of elevated blood glucose levels.
The very low risk of hypoglycemia associated with these
treatments is an important aspect when considering their
use in patients with renal impairment. Apart from stimu-
lating insulin secretion, GLP-1 reduces glucagon secretion
and hepatic glucose production. GLP-1 receptor agonists,
in particular the short acting ones (Exenatide) slow gastric
emptying considerably, and also, increase satiety with a de-
crease in food intake like with the longer acting agonists
(liraglutide or extended-release exenatide)
GLP-1 receptor agonists
GLP-1 receptor agonists are a treatment option for patients
who fail to achieve adequate blood glucose control with
metformin alone or with multiple oral antidiabetic drugs.
These drugs are particularly useful when the goal is not
only to improve diabetes treatment, but also to favour
weight loss, especially in very obese patients at risk of
gaining even more weight when starting insulin therapy.
Exenatide (Byetta®) is given by 5–10 μg sub-cutaneous
injections twice a day and decreases glycosylated hemo-
globin by approximately 0.7% to 1.5%, depending on
baseline HbA1C.
Exenatide is primarily eliminated by glomerular filtration,
followed by proteolytic breakdown. In patients with mild-
to-moderate renal impairment, exenatide clearance is
slightly reduced compared to subjects with no renal impair-
ment (13% reduction in mild renal impairment and 36%
reduction in moderate renal impairment). In patients with
severe renal impairment or dialysis patients, clearance is
reduced by 84%.
Exenatide is not recommended in patients with severe renal
impairment (GFR <30 ml/min). In patients with a GFR of
30–60 ml/min, exenatide should only be used with great
caution and at lower doses, as the incidence and intensity
of gastrointestinal side effects are likely to increase. Clin-
ical experience in these patients is very limited. The use of
Bydureon® (extended release exenatide) is not recommen-
ded in CKD stage 3 and beyond.
GLP-1 receptors are expressed in renal tubules, and GLP-1
receptor agonists have been shown to have diuretic prop-
erties. As a result, the diuretic effect of such treatment
may exacerbate renal impairment, especially in patients
taking renin-angiotensin system inhibitors or diuretics. The
extracelluar volume contraction can also be worsened by
the gastro-intestinal side effects (vomiting) and precipitate
acute renal failure. In addition, subjects with advanced kid-
ney disease and diabetes frequently have autonomic neuro-
pathy which exacerbate the gastric side effects of GLP-1
receptor agonists.
Liraglutide (Victoza®) is given by 0.6 to 1.8 mg subcu-
taneous injections once daily. Its efficacy with regard to
HbA1c lowering is superior to the shorter acting analogs
(Exenatide) due to the lowering of fasting glucose. The ef-
fect on weight is comparable [18].
Liraglutide is metabolised in a similar manner to large pro-
teins, and no specific organ is responsible for its elimin-
ation. Intact liraglutide is recovered neither in the urine
nor in the feces. Its elimination half-life is approximately
13 hours.
Unlike exenatide, liraglutide shows no increase in half-life
and hence no reduced clearance in patients with mild, mod-
erate, or even severe renal impairment. Therefore, the kid-
ney is not a major site of liraglutide elimination or break-
down. Patients with mild renal impairment require no dose
adjustment. Experience with liraglutide is however very
limited in patients with moderate renal impairment and
nonexistent in those with severe renal impairment. There-
fore, this treatment is contraindicated in these settings.
DPP4 Inhibitors
Inhibitors of the DPP4 enzyme (gliptins) are not a homo-
geneous class of drugs; they have different chemical and
pharmacokinetic properties (table 2), but share the same
mechanism of action: inhibition of the DPP4 enzyme.
Gliptins are less effective on average than GLP-1 receptor
agonists as they achieve a reduction in glycosylated
haemoglobin by approximately 0.6% to 1%. They are used
either in combination with metformin or as add-on therapy
to a combination of two antidiabetic drugs.
Sitagliptin (Januvia®, Xelevia®) shows high plasma pro-
tein binding. Sitagliptin is eliminated predominantly un-
changed, via the urine (87%) or via the feces (13%).
In patients with mild, moderate or severe renal impairment,
or dialysis patients, the increase in sitagliptin plasma levels
is respectively 1.7, 2.3, 3.8 or 4.5 fold compared to con-
trols. Therefore, the half-life of sitagliptin in patients with
renal impairment is increased and correlated with the de-
gree of renal impairment.
No dose adjustment is necessary in patients with mild renal
impairment (GFR >50 ml/min). Patients with moderate
renal impairment (GFR 30–50 ml/min) need to have their
dose reduced by half to 50 mg/day. Patients with GFR <30
ml/min or requiring dialysis may be treated with 25 mg/
day, but clinical experience is very limited in these patients.
When sitagliptin is combined with metformin, the contrain-
dications to metformin should obviously be considered, es-
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pecially if GFR is <45 ml/min. This applies to all gliptins
used in combination with metformin.
Around 80% of a Vildagliptin (Galvus®) dose is meta-
bolised into non-active metabolites by various mechanisms
that do not involve cytochrome P450 enzymes; 20% of
a dose is thus not metabolised. Approximately 85% of a
vildagliptin dose is eliminated in the urine, and 15% is re-
covered in the feces.
Exposure to vildagliptin in patients with moderate-to-
severe renal impairment is increased compared to controls.
However, the degree of exposure to vildagliptin does not
correspond to the severity of renal impairment. Therefore,
vildagliptin can be used without dose adjustment in pa-
tients whose creatinine clearance is >50 ml/min. While
vildagliptin is, in principle, contraindicated in patients with
moderate-to-severe renal impairment, a recent 24-week
study suggests that vildagliptin 50 mg is effective and well
tolerated in this setting [19].
Saxagliptin (Onglyza®) is excreted primarily by the kid-
neys, with approximately 20% of a dose being recovered
unchanged in the urine and 20–50% as metabolites.
Saxagliptin metabolism is essentially mediated by cyto-
chrome 3A4/5 enzymes, thus the co-administration of
saxagliptin with cytochrome 3A4/5 inhibitors requires a
dose reduction by half. Saxagliptin metabolites still have
50% of the activity of the parent compound.
Saxagliptin is thus eliminated both by biotransformation
and by renal excretion. In patients with mild renal impair-
ment, patient exposure to saxagliptin and to its major meta-
bolites was respectively 1.2 and 1.7 fold greater compared
to controls. Values for patients with moderate renal impair-
ment were 1.4 and 2.9 fold higher and those for patients
Table 1: Clinical practice recommendations.
Class Drug T1/2 Duration
of action
Use in case of renal impairment Dialysis
Glibenclamide 6–10 h 18–24 h
Glimepiride 5–7 h >24 h
GFR >60
GFR <60
Yes
No
NoSulfonylureas
Gliclazide 6–15 h 18–24 h GFR >60
GFR: 40–60
GFR <40
Yes
With caution
No
No
Repaglinide 0.6–1.8 h 4–6 h Yes YesGlinides
Nateglinide 1.2–1.8 h 4 h With caution No
Biguanide Metformin 4–9 h GFR >60
GFR: 45–60
Yes
With caution, only in the absence of conditions that
may increase the risk of lactic acidosis.
No
Glitazone Pioglitazone 3–7 h
Active and inactive
metabolites: 16–24 h
GFR >60
GFR <60
Yes
With caution, risk of water and sodium retention.
Limited experience;
great caution.
Alpha-
glucosidase
inhibitors
Acarbose GFR >60
GFR <60
Yes
No
No
Exenatide 2.4 h GFR >60
GFR: 30–60
GFR <30
Yes
Limited experience; with caution.
No
NoGLP-1 receptor
agonists
Liraglutide 13 h GFR >50
GFR <50
Yes
No
No
Sitagliptin 8–24 h GFR >50
GFR: 30–50
GFR <30
Yes
50 mg/day
25 mg/day, limited experience
Limited experience,
with caution.
Vildagliptin 1.5–4.5 hrs GFR >50
GFR <50
Yes
No
No
Saxagliptin 2–4 hrs GFR >50
GFR: 30–50
GFR: 15–30
Yes
2.5 mg/day
2.5 mg/day; limited experience
No (CH);
limited experience,
with caution (US)
DPP-4 inhibitors
Linagliptin 10–40 hrs GFR >50
GFR <50
Yes
Yes; limited experience
No experience, with
caution.
Table 2: Pharmacokinetic properties of incretins.
Sitagliptin
(Januvia®; Xelevia®)
Vildagliptin
(Galvus®)
Saxagliptin
(Onglyza®)
Linagliptin
(Trajenta®)
Exenatide
(Byetta®)
Liraglutide
(Victoza®)
Dose (mg/day) 25–100 50–100 2.5–5 5 5–10 μg/day 0.6–1.8 mg/day
Administration OD BID OD OD BID OD
Plasma protein binding Intermediate Low Very low High Low High
Renal excretion Predominant Intermediate Predominant Very low Predominant No
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with severe renal impairment were 2.1 and 4.5 fold higher.
Therefore, no dose adjustment is required for patients with
mild renal impairment, whereas dose reduction by half is
necessary for patients with moderate renal impairment. The
use of saxagliptin is not recommended for patients with a
more severe degree of renal impairment although recent
data suggest that saxagliptin is effective and well tolerated
in this setting [20].
Linagliptin (Trajenta®) was accepted in Switzerland in
March 2012 for the treatment of type 2 diabetes. Linaglipt-
in shows very high plasma protein binding and is subject
to little biotransformation. Its elimination is essentially via
the feces. As the elimination of linagliptin via the kidneys
is extremely low (approximately 1%), no dose adjustment
is required for any degree of renal impairment [21, 22].
Recapitulation
In summary (table 1 and 2), there are significant differen-
ces between the various gliptins. Sitagliptin has a relatively
long half-life, no active metabolites, and significant renal
excretion; it is therefore necessary to adjust the sitaglipt-
in dose as a function of renal impairment. Vildagliptin has
a much shorter half-life, with only a quarter of the act-
ive metabolite eliminated by the kidney. No dose adjust-
ment is necessary in patients with mild renal impairment,
but is required in more advanced stages of renal impair-
ment. Saxagliptin also has a short half-life, but has active
metabolites. Both saxagliptin and its main metabolite are
excreted via the kidneys; therefore, dose adjustment is ne-
cessary in case of renal impairment. Linagliptin is subject
to high plasma protein binding, has a relatively long half-
life, and is subject to virtually no renal excretion and, there-
fore, requires no dose adjustment in patients with kidney
disease.
In addition to the degradation of GLP-1, the DPP-IV en-
zyme is involved in the catabolism of other important pro-
teins such as substance P. We should remain cautious about
the use of DPP-IV inhibitors in metabolically complex situ-
ations like severe chronic kidney disease. Because the in-
crease in substance P has been linked to ACE inhibitor
(ACEI) induced angiooedema, there has been some con-
cern that the association of an ACEI with a DPP-IV in-
hibitor could exacerbate the risk of angiooedema [23]. A
meta-analysis of phase 3 trials showed that although DPP-
IV inhibitor therapy alone did not increase the risk of an-
giooedema, there were clearly more cases when associated
with ACEI, but not with angiotensin receptor blockers
(ARB) [24]. These findings need confirmation but could
be an argument to favour the association of DPP-IV with
ARB’s rather than with ACEIs.
Conclusion
With the increasing incidence of type 2 diabetic subjects
with renal impairment, regular kidney function monitoring
and adjustment of antidiabetic drug therapy according to
GFR and pharmacokinetic data are of major importance.
Because large studies of the safety of oral hypoglycaemic
agents in renal failure are lacking, these recommendations
will need to be regularly updated following the results of
larger randomised trials with longer follow-ups.
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Figures (large format)
Figure 1
Antidiabetic treatment in chronic renal failure according to the KDIGO staging of CKD. Adapted from: Schernthaner G, Ritz E, Schernthaner GH.
Strict glycaemic control in diabetic patients with CKD or ESRD: beneficial or deadly? Nephrol Dial Transplant. 2010;25:2044–7 [25] (© 2010,
Oxford University Press. Reprinted with permission).
Recommendations adapted to stages of CKD based on a consensus from pharmacological data, Swiss and international recommendations.
1 Limited experience (dotted line); 2 monitor for fluid retention; 3 avoid introducing as new therapy or if conditions increasing lactic acidosis risk.
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